Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017
Background Osteosarcoma is the most common primary bone malignancy. As a rare cancer, population‐based studies remain small with limited information on finer demographic categories. Recent studies have reported important genetic differences based on age and ethnicity, and more detailed studies are n...
Saved in:
| Published in: | Cancer Vol. 128; no. 11; pp. 2107 - 2118 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Wiley Subscription Services, Inc
01.06.2022
|
| Subjects: | |
| ISSN: | 0008-543X, 1097-0142, 1097-0142 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
Osteosarcoma is the most common primary bone malignancy. As a rare cancer, population‐based studies remain small with limited information on finer demographic categories. Recent studies have reported important genetic differences based on age and ethnicity, and more detailed studies are needed to better understand potentially important osteosarcoma risk groups.
Methods
Incidence and survival rates for 5016 patients with osteosarcoma from the Surveillance, Epidemiology, and End Results (SEER) program (1975‐2017) were analyzed by age (0‐9, 10‐24, 25‐59, and >60 years old), race/ethnicity, histologic subtype, stage, and tumor location using SEER*Stat software.
Results
For cases 0 to 9 years old, incidence of primary osteosarcoma was similar between the sexes, increased significantly throughout the study period (P < .05), and the 5‐year relative survival has steadily increased over time. Blacks had the highest incidence in all aged cases combined and a significant increase in incidence throughout the study period (P < .05). Overall, survival rates for all cases have remained relatively unchanged over recent decades, with worse survival observed in males, American Indian/Alaska Native cases, older patients, metastatic disease, axial tumors, and subsequent osteosarcoma cases. For cases 0 to 24 years old, the incidence of subsequent osteosarcoma increased 3‐fold since the 2000s.
Conclusion
Important differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma, are identified. A genetic risk factor may be associated with observed ancestry‐specific incidence differences and illustrates the importance of analyzing osteosarcoma by specific age groups and ethnicities to better understand their unique epidemiology and underlying biology.
Lay Summary
Osteosarcoma is the most common bone cancer, but still a relatively rare disease, and previous studies have had limited information on finer demographics.
Using a large database, osteosarcoma incidence and survival patterns are thoroughly evaluated and important differences, especially for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are identified.
Important differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are identified in this study. Analyzing osteosarcoma by specific age groups and ethnicities is important to better understand the unique epidemiology and underlying biology. |
|---|---|
| AbstractList | Osteosarcoma is the most common primary bone malignancy. As a rare cancer, population-based studies remain small with limited information on finer demographic categories. Recent studies have reported important genetic differences based on age and ethnicity, and more detailed studies are needed to better understand potentially important osteosarcoma risk groups.BACKGROUNDOsteosarcoma is the most common primary bone malignancy. As a rare cancer, population-based studies remain small with limited information on finer demographic categories. Recent studies have reported important genetic differences based on age and ethnicity, and more detailed studies are needed to better understand potentially important osteosarcoma risk groups.Incidence and survival rates for 5016 patients with osteosarcoma from the Surveillance, Epidemiology, and End Results (SEER) program (1975-2017) were analyzed by age (0-9, 10-24, 25-59, and >60 years old), race/ethnicity, histologic subtype, stage, and tumor location using SEER*Stat software.METHODSIncidence and survival rates for 5016 patients with osteosarcoma from the Surveillance, Epidemiology, and End Results (SEER) program (1975-2017) were analyzed by age (0-9, 10-24, 25-59, and >60 years old), race/ethnicity, histologic subtype, stage, and tumor location using SEER*Stat software.For cases 0 to 9 years old, incidence of primary osteosarcoma was similar between the sexes, increased significantly throughout the study period (P < .05), and the 5-year relative survival has steadily increased over time. Blacks had the highest incidence in all aged cases combined and a significant increase in incidence throughout the study period (P < .05). Overall, survival rates for all cases have remained relatively unchanged over recent decades, with worse survival observed in males, American Indian/Alaska Native cases, older patients, metastatic disease, axial tumors, and subsequent osteosarcoma cases. For cases 0 to 24 years old, the incidence of subsequent osteosarcoma increased 3-fold since the 2000s.RESULTSFor cases 0 to 9 years old, incidence of primary osteosarcoma was similar between the sexes, increased significantly throughout the study period (P < .05), and the 5-year relative survival has steadily increased over time. Blacks had the highest incidence in all aged cases combined and a significant increase in incidence throughout the study period (P < .05). Overall, survival rates for all cases have remained relatively unchanged over recent decades, with worse survival observed in males, American Indian/Alaska Native cases, older patients, metastatic disease, axial tumors, and subsequent osteosarcoma cases. For cases 0 to 24 years old, the incidence of subsequent osteosarcoma increased 3-fold since the 2000s.Important differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma, are identified. A genetic risk factor may be associated with observed ancestry-specific incidence differences and illustrates the importance of analyzing osteosarcoma by specific age groups and ethnicities to better understand their unique epidemiology and underlying biology.CONCLUSIONImportant differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma, are identified. A genetic risk factor may be associated with observed ancestry-specific incidence differences and illustrates the importance of analyzing osteosarcoma by specific age groups and ethnicities to better understand their unique epidemiology and underlying biology.Osteosarcoma is the most common bone cancer, but still a relatively rare disease, and previous studies have had limited information on finer demographics. Using a large database, osteosarcoma incidence and survival patterns are thoroughly evaluated and important differences, especially for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are identified.LAY SUMMARYOsteosarcoma is the most common bone cancer, but still a relatively rare disease, and previous studies have had limited information on finer demographics. Using a large database, osteosarcoma incidence and survival patterns are thoroughly evaluated and important differences, especially for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are identified. Osteosarcoma is the most common primary bone malignancy. As a rare cancer, population-based studies remain small with limited information on finer demographic categories. Recent studies have reported important genetic differences based on age and ethnicity, and more detailed studies are needed to better understand potentially important osteosarcoma risk groups. Incidence and survival rates for 5016 patients with osteosarcoma from the Surveillance, Epidemiology, and End Results (SEER) program (1975-2017) were analyzed by age (0-9, 10-24, 25-59, and >60 years old), race/ethnicity, histologic subtype, stage, and tumor location using SEER*Stat software. For cases 0 to 9 years old, incidence of primary osteosarcoma was similar between the sexes, increased significantly throughout the study period (P < .05), and the 5-year relative survival has steadily increased over time. Blacks had the highest incidence in all aged cases combined and a significant increase in incidence throughout the study period (P < .05). Overall, survival rates for all cases have remained relatively unchanged over recent decades, with worse survival observed in males, American Indian/Alaska Native cases, older patients, metastatic disease, axial tumors, and subsequent osteosarcoma cases. For cases 0 to 24 years old, the incidence of subsequent osteosarcoma increased 3-fold since the 2000s. Important differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma, are identified. A genetic risk factor may be associated with observed ancestry-specific incidence differences and illustrates the importance of analyzing osteosarcoma by specific age groups and ethnicities to better understand their unique epidemiology and underlying biology. Osteosarcoma is the most common bone cancer, but still a relatively rare disease, and previous studies have had limited information on finer demographics. Using a large database, osteosarcoma incidence and survival patterns are thoroughly evaluated and important differences, especially for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are identified. Important differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are identified in this study. Analyzing osteosarcoma by specific age groups and ethnicities is important to better understand the unique epidemiology and underlying biology. Background Osteosarcoma is the most common primary bone malignancy. As a rare cancer, population‐based studies remain small with limited information on finer demographic categories. Recent studies have reported important genetic differences based on age and ethnicity, and more detailed studies are needed to better understand potentially important osteosarcoma risk groups. Methods Incidence and survival rates for 5016 patients with osteosarcoma from the Surveillance, Epidemiology, and End Results (SEER) program (1975‐2017) were analyzed by age (0‐9, 10‐24, 25‐59, and >60 years old), race/ethnicity, histologic subtype, stage, and tumor location using SEER*Stat software. Results For cases 0 to 9 years old, incidence of primary osteosarcoma was similar between the sexes, increased significantly throughout the study period (P < .05), and the 5‐year relative survival has steadily increased over time. Blacks had the highest incidence in all aged cases combined and a significant increase in incidence throughout the study period (P < .05). Overall, survival rates for all cases have remained relatively unchanged over recent decades, with worse survival observed in males, American Indian/Alaska Native cases, older patients, metastatic disease, axial tumors, and subsequent osteosarcoma cases. For cases 0 to 24 years old, the incidence of subsequent osteosarcoma increased 3‐fold since the 2000s. Conclusion Important differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma, are identified. A genetic risk factor may be associated with observed ancestry‐specific incidence differences and illustrates the importance of analyzing osteosarcoma by specific age groups and ethnicities to better understand their unique epidemiology and underlying biology. Lay Summary Osteosarcoma is the most common bone cancer, but still a relatively rare disease, and previous studies have had limited information on finer demographics. Using a large database, osteosarcoma incidence and survival patterns are thoroughly evaluated and important differences, especially for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are identified. Important differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are identified in this study. Analyzing osteosarcoma by specific age groups and ethnicities is important to better understand the unique epidemiology and underlying biology. BackgroundOsteosarcoma is the most common primary bone malignancy. As a rare cancer, population‐based studies remain small with limited information on finer demographic categories. Recent studies have reported important genetic differences based on age and ethnicity, and more detailed studies are needed to better understand potentially important osteosarcoma risk groups.MethodsIncidence and survival rates for 5016 patients with osteosarcoma from the Surveillance, Epidemiology, and End Results (SEER) program (1975‐2017) were analyzed by age (0‐9, 10‐24, 25‐59, and >60 years old), race/ethnicity, histologic subtype, stage, and tumor location using SEER*Stat software.ResultsFor cases 0 to 9 years old, incidence of primary osteosarcoma was similar between the sexes, increased significantly throughout the study period (P < .05), and the 5‐year relative survival has steadily increased over time. Blacks had the highest incidence in all aged cases combined and a significant increase in incidence throughout the study period (P < .05). Overall, survival rates for all cases have remained relatively unchanged over recent decades, with worse survival observed in males, American Indian/Alaska Native cases, older patients, metastatic disease, axial tumors, and subsequent osteosarcoma cases. For cases 0 to 24 years old, the incidence of subsequent osteosarcoma increased 3‐fold since the 2000s.ConclusionImportant differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma, are identified. A genetic risk factor may be associated with observed ancestry‐specific incidence differences and illustrates the importance of analyzing osteosarcoma by specific age groups and ethnicities to better understand their unique epidemiology and underlying biology.Lay SummaryOsteosarcoma is the most common bone cancer, but still a relatively rare disease, and previous studies have had limited information on finer demographics.Using a large database, osteosarcoma incidence and survival patterns are thoroughly evaluated and important differences, especially for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are identified. |
| Author | Zhu, Bin Gianferante, D. Matthew Mirabello, Lisa Cole, Sarah |
| AuthorAffiliation | 2 Walter Reed National Military Medical Center, Bethesda, Maryland 1 Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 3 Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland |
| AuthorAffiliation_xml | – name: 3 Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland – name: 2 Walter Reed National Military Medical Center, Bethesda, Maryland – name: 1 Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland |
| Author_xml | – sequence: 1 givenname: Sarah surname: Cole fullname: Cole, Sarah organization: Walter Reed National Military Medical Center – sequence: 2 givenname: D. Matthew orcidid: 0000-0003-4126-2093 surname: Gianferante fullname: Gianferante, D. Matthew organization: National Institutes of Health – sequence: 3 givenname: Bin surname: Zhu fullname: Zhu, Bin organization: National Institutes of Health – sequence: 4 givenname: Lisa surname: Mirabello fullname: Mirabello, Lisa email: mirabellol@mail.nih.gov organization: National Institutes of Health |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35226758$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kd9qFDEYxYNU7LZ64wNIwBspnZr_mXgjZVn_QLFQFbwLmUxmTclMtslMZe_6CD6jT2LGbUWLeBE-wvc7h8N3DsDeEAcHwFOMTjBC5KUdbDqhDAv6ACwwUrJCmJE9sEAI1RVn9Ms-OMj5snwl4fQR2KecECF5vQDdeR5dzCbZ2JtX8BR-nNK18yGYwbpjuNr41vU-hrjeHkMztHBV3oXLUxgz3KS4Tqb_cfO9Mdm1ZW_CNvsMuxR7iJXkcIyQICwfg4edCdk9uZ2H4POb1aflu-rs_O375elZZRlTtGKOEmJR1zDVcUORbCR2NWlUQ1iLGiJrbqXillopLG_bxioi2tZIxyRusKKH4PXOdzM1vWutG8Zkgt4k35u01dF4_fdm8F_1Ol5rjAWTXIji8OLWIcWryeVR9z5bNx_ExSlrIiirS1aBCvr8HnoZp1RuMFMCKUYZYoV69mek31nuOigA2gE2xZyT67T1oxl9nBP6oDHSc816rln_qrlIju5J7lz_CeMd_M0Ht_0PqZcflhc7zU9sLbgU |
| CitedBy_id | crossref_primary_10_1039_D5TB00364D crossref_primary_10_1002_pbc_31808 crossref_primary_10_3390_diagnostics15030266 crossref_primary_10_3390_ijms241411367 crossref_primary_10_1002_adtp_202500167 crossref_primary_10_2106_JBJS_CC_23_00089 crossref_primary_10_1016_j_jcot_2025_103173 crossref_primary_10_1016_j_phymed_2025_156464 crossref_primary_10_3390_ijms242015474 crossref_primary_10_3389_fimmu_2025_1647913 crossref_primary_10_1371_journal_pone_0326872 crossref_primary_10_1016_j_biopha_2024_116570 crossref_primary_10_1007_s11010_024_05135_5 crossref_primary_10_1016_j_biomaterials_2024_122683 crossref_primary_10_1016_j_compmedimag_2025_102522 crossref_primary_10_3724_abbs_2024084 crossref_primary_10_3390_biom12101420 crossref_primary_10_1016_j_hoc_2025_04_005 crossref_primary_10_1002_pbc_31362 crossref_primary_10_1002_path_6384 crossref_primary_10_1055_s_0043_1771483 crossref_primary_10_2147_CMAR_S542371 crossref_primary_10_1038_s41598_025_05293_6 crossref_primary_10_1038_s41598_024_67386_y crossref_primary_10_3390_cancers16091648 crossref_primary_10_1007_s00210_023_02903_w crossref_primary_10_1016_j_cancergen_2025_08_008 crossref_primary_10_1177_09287329251360524 crossref_primary_10_1016_j_advop_2025_09_001 crossref_primary_10_1111_vco_12993 crossref_primary_10_1097_RLI_0000000000001030 crossref_primary_10_7759_cureus_56030 crossref_primary_10_3390_cancers17172755 crossref_primary_10_1186_s12889_023_17571_x crossref_primary_10_1038_s41598_023_45566_6 crossref_primary_10_1038_s44276_024_00120_3 crossref_primary_10_3390_cancers16010201 crossref_primary_10_3390_ijms24098401 crossref_primary_10_1016_j_jksus_2024_103405 crossref_primary_10_1038_s41420_025_02541_6 crossref_primary_10_3390_cancers15205108 crossref_primary_10_1097_MD_0000000000030981 crossref_primary_10_1002_adfm_202422469 crossref_primary_10_3390_diagnostics15050644 crossref_primary_10_3390_cimb47010021 crossref_primary_10_1016_j_semcancer_2023_07_003 crossref_primary_10_3389_fonc_2024_1338811 crossref_primary_10_1186_s40575_023_00131_2 crossref_primary_10_3389_fphar_2025_1529525 crossref_primary_10_1002_jso_27361 crossref_primary_10_1038_s41416_024_02868_4 crossref_primary_10_1002_cac2_12653 crossref_primary_10_1016_j_heliyon_2023_e23499 crossref_primary_10_1177_10732748251364041 crossref_primary_10_3389_fonc_2023_1200203 crossref_primary_10_1038_s41388_024_03205_y crossref_primary_10_3389_fonc_2025_1509170 crossref_primary_10_34133_research_0708 crossref_primary_10_1007_s11042_024_19554_5 crossref_primary_10_1016_j_pbiomolbio_2024_04_003 crossref_primary_10_3390_cancers16091628 crossref_primary_10_3389_fonc_2023_1227461 crossref_primary_10_1186_s12864_024_10283_5 crossref_primary_10_1016_j_thorsurg_2024_12_002 crossref_primary_10_1002_advs_202310167 crossref_primary_10_1097_MD_0000000000040240 crossref_primary_10_1002_pbc_30752 crossref_primary_10_1111_jcmm_18278 crossref_primary_10_1002_pbc_31453 crossref_primary_10_1007_s12094_025_03901_5 crossref_primary_10_1002_ijc_34694 crossref_primary_10_1016_j_canep_2024_102551 crossref_primary_10_1093_jjco_hyaf094 crossref_primary_10_1016_j_canep_2023_102398 crossref_primary_10_1016_j_canep_2023_102432 crossref_primary_10_1016_j_jddst_2023_104356 crossref_primary_10_2147_OTT_S494899 crossref_primary_10_1016_j_ijpharm_2025_125372 crossref_primary_10_3390_life13030744 crossref_primary_10_1007_s00432_023_04614_4 crossref_primary_10_1007_s10147_024_02673_2 crossref_primary_10_1093_jjco_hyaf086 crossref_primary_10_3390_gels9040274 crossref_primary_10_3389_fpubh_2025_1481304 crossref_primary_10_5435_JAAOSGlobal_D_24_00130 crossref_primary_10_3390_diagnostics15131707 crossref_primary_10_3390_cells13030233 crossref_primary_10_69854_jcq_2025_0013 crossref_primary_10_1016_j_canep_2024_102565 crossref_primary_10_3389_fmed_2022_1058863 crossref_primary_10_1038_s41572_022_00409_y crossref_primary_10_1186_s12935_025_03659_4 crossref_primary_10_2147_JIR_S440459 crossref_primary_10_3389_fimmu_2024_1362970 crossref_primary_10_1007_s13755_024_00288_5 crossref_primary_10_1007_s00701_025_06538_z crossref_primary_10_1002_btm2_10654 crossref_primary_10_1016_j_cej_2024_150631 crossref_primary_10_1038_s41419_024_06444_9 crossref_primary_10_1016_j_omto_2023_100736 crossref_primary_10_1097_PAP_0000000000000476 crossref_primary_10_3390_diagnostics15030328 crossref_primary_10_1016_j_jbo_2024_100652 crossref_primary_10_3390_children10040736 crossref_primary_10_1186_s12967_022_03828_3 crossref_primary_10_1002_pbc_30583 crossref_primary_10_1016_j_bcp_2023_115472 crossref_primary_10_1097_CCO_0000000000001046 crossref_primary_10_1002_jgm_3563 crossref_primary_10_1016_j_matdes_2024_113016 crossref_primary_10_3390_cancers17010097 crossref_primary_10_1155_2022_5040458 crossref_primary_10_1186_s13018_024_04781_1 crossref_primary_10_3389_fgene_2022_944978 crossref_primary_10_3389_fimmu_2024_1403538 crossref_primary_10_1016_j_actbio_2025_08_046 crossref_primary_10_2147_IJN_S471900 crossref_primary_10_1186_s12964_024_01811_7 crossref_primary_10_3389_fonc_2023_1130215 crossref_primary_10_3389_fcacs_2025_1572317 crossref_primary_10_1016_j_biopha_2024_116235 crossref_primary_10_1016_j_bbrc_2025_151491 crossref_primary_10_3390_cancers15061818 crossref_primary_10_1038_s41598_025_13324_5 crossref_primary_10_1089_gtmb_2024_0080 crossref_primary_10_1186_s12957_025_03715_3 crossref_primary_10_1016_j_ejmech_2025_117279 crossref_primary_10_1038_s41598_023_46857_8 crossref_primary_10_1016_j_bbcan_2024_189171 crossref_primary_10_3389_fimmu_2025_1577261 crossref_primary_10_3390_biom13020398 crossref_primary_10_1016_j_jbo_2023_100491 crossref_primary_10_1186_s40001_023_01139_x crossref_primary_10_3390_ph17111526 crossref_primary_10_7759_cureus_49276 crossref_primary_10_1016_j_jpedsurg_2025_162202 crossref_primary_10_3389_fimmu_2023_1188256 crossref_primary_10_1002_adfm_202507822 crossref_primary_10_1186_s12967_025_06248_1 crossref_primary_10_26599_NR_2025_94907755 |
| Cites_doi | 10.1200/jco.2007.14.9104 10.1002/jso.22122 10.3390/ijerph120911178 10.7150/jca.32627 10.1016/j.ejca.2018.11.027 10.1007/s11864‐009‐0087‐3 10.1002/cncr.24121 10.1002/cam4.1706 10.1016/s1470‐2045(16)30096‐1 10.1590/1516‐3180.2018.0381120619 10.1001/jama.1997.03550150066037 10.47102/annals-acadmedsg.V41N9p390 10.1002/(sici)1097‐0215(19980729)77:3<370::aid‐ijc11>3.0.co;2‐c 10.1093/jnci/djv101 10.1002/pbc.22509 10.1001/jamaoncol.2020.0197 10.1038/nrclinonc.2014.175 10.1038/nrendo.2017.16 10.1200/jco.2014.60.0734 10.1089/152460902760360568 10.3892/mco.2018.1752 10.3390/jcm10061182 10.1007/s10552‐011‐9740‐9 10.1093/annonc/mdn731 10.1001/archsurg.1992.01420120013002 10.1016/s1470‐2045(16)30214‐5 10.1007/s10552-011-9763-2 10.1016/j.critrevonc.2020.103126 10.1016/j.oraloncology.2013.10.017 10.1080/07357907.2020.1768401 10.1051/sicotj/2017028 10.1002/ijc.24320 10.1089/152460902760360559 10.1002/cncr.30248 10.1016/j.canep.2015.05.001 10.21037/aoj.2019.12.03 10.1002/cam4.1659 10.7759/cureus.1418 10.1177/1073274819888893 10.2307/2531329 10.1158/1055‐9965.epi‐11‐0136 |
| ContentType | Journal Article |
| Copyright | Published 2022. This article is a U.S. Government work and is in the public domain in the USA. 2022 American Cancer Society |
| Copyright_xml | – notice: Published 2022. This article is a U.S. Government work and is in the public domain in the USA. – notice: 2022 American Cancer Society |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| DOI | 10.1002/cncr.34163 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0142 |
| EndPage | 2118 |
| ExternalDocumentID | PMC11647566 35226758 10_1002_cncr_34163 CNCR34163 |
| Genre | article Journal Article Research Support, N.I.H., Intramural |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: Intramural NIH HHS grantid: ZIA CP010142 |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AARRQ AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEIGN AEIMD AENEX AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ .Y3 31~ 3O- AAMMB AAQOH AAYXX AEFGJ AEYWJ AFFNX AGHNM AGNAY AGXDD AGYGG AI. AIDQK AIDYY C1A CITATION EJD HF~ H~9 J5H LW6 N4W NEJ O8X OHT RSU VH1 WHG Y6R YQJ ZXP CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| ID | FETCH-LOGICAL-c4493-4e322c0fb49f5a307b71e82b9b24d0b2785c795c3c76c5ddbc926dda7e471b193 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 164 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000761951200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Tue Sep 30 17:05:55 EDT 2025 Thu Oct 02 06:10:51 EDT 2025 Tue Oct 07 06:52:39 EDT 2025 Mon Jul 21 05:45:52 EDT 2025 Sat Nov 29 07:17:04 EST 2025 Tue Nov 18 22:28:47 EST 2025 Wed Jan 22 16:24:41 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | epidemiology SEER incidence osteosarcoma |
| Language | English |
| License | Published 2022. This article is a U.S. Government work and is in the public domain in the USA. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4493-4e322c0fb49f5a307b71e82b9b24d0b2785c795c3c76c5ddbc926dda7e471b193 |
| Notes | The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government. The first two authors contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 AUTHOR CONTRIBUTIONS All authors contributed to conceptualization, formal analysis, resources, and writing of the manuscript. |
| ORCID | 0000-0003-4126-2093 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/11647566 |
| PMID | 35226758 |
| PQID | 2660943404 |
| PQPubID | 2045183 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11647566 proquest_miscellaneous_2634849360 proquest_journals_2660943404 pubmed_primary_35226758 crossref_citationtrail_10_1002_cncr_34163 crossref_primary_10_1002_cncr_34163 wiley_primary_10_1002_cncr_34163_CNCR34163 |
| PublicationCentury | 2000 |
| PublicationDate | June 1, 2022 |
| PublicationDateYYYYMMDD | 2022-06-01 |
| PublicationDate_xml | – month: 06 year: 2022 text: June 1, 2022 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2022 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 1997; 278 2015; 12 2010; 55 2015; 39 2019; 4 2009; 20 2019; 10 2015; 33 2002; 11 1992; 127 2020; 38 2016; 122 2019; 109 2015; 107 1983; 39 2016; 17 2012; 105 2017; 9 2009; 115 2018; 7 2020; 6 2021; 10 2009; 10 2018; 4 2020 2019; 26 2017; 13 2011; 20 2019; 137 2008; 26 2011; 22 2020; 156 2014; 50 2009; 125 1998; 77 2014; 11 2012; 41 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 Surveillance Research Program (e_1_2_8_20_1) 2020 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_43_1 Surveillance, Epidemiology, and End Results Program (e_1_2_8_19_1) 2020 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_41_1 e_1_2_8_40_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 |
| References_xml | – volume: 105 start-page: 570 year: 2012 end-page: 576 article-title: Post‐radiation sarcomas. Clinical outcome of 52 patients publication-title: J Surg Oncol – volume: 33 start-page: 2279 year: 2015 end-page: 2287 article-title: Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alpha‐2b versus map alone in patients with resectable high‐grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS‐1 Good Response Randomized Controlled Trial publication-title: J Clin Oncol – volume: 10 start-page: 4614 year: 2019 end-page: 4622 article-title: Predictors of the survival of primary and secondary older osteosarcoma patients publication-title: J Cancer – volume: 10 start-page: 1182 year: 2021 article-title: Pathogenesis and current treatment of osteosarcoma: perspectives for future therapies publication-title: J Clin Med – volume: 7 start-page: 3652 year: 2018 end-page: 3661 article-title: Increased survival of patients aged 0‐29 years with osteosarcoma: a period analysis, 1984‐2013 publication-title: Cancer Med – volume: 127 start-page: 1379 year: 1992 end-page: 1385 article-title: Radiation‐associated sarcoma of bone and soft tissue publication-title: Arch Surg – volume: 6 start-page: 724 year: 2020 end-page: 734 article-title: Frequency of pathogenic germline variants in cancer‐susceptibility genes in patients with osteosarcoma publication-title: JAMA Oncol – volume: 122 start-page: 3673 year: 2016 end-page: 3681 article-title: Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort publication-title: Cancer – volume: 77 start-page: 370 year: 1998 end-page: 377 article-title: Radiation dose, chemotherapy and risk of osteosarcoma after solid tumors during childhood publication-title: Int J Cancer – volume: 39 start-page: 941 year: 1983 end-page: 948 article-title: The statistical comparison of relative survival rates publication-title: Biometrics – volume: 10 start-page: 153 year: 2019 end-page: 158 article-title: Secondary osteosarcoma in patients previously treated for childhood cancer: three case reports publication-title: Mol Clin Oncol – volume: 10 start-page: 82 year: 2009 end-page: 93 article-title: The multidisciplinary management of osteosarcoma publication-title: Curr Treat Options Oncol – volume: 11 start-page: 740 year: 2014 end-page: 750 article-title: Childhood cancer survivor care: development of the Passport for Care publication-title: Nat Rev Clin Oncol – volume: 17 start-page: 1396 year: 2016 end-page: 1408 article-title: Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high‐grade osteosarcoma (EURAMOS‐1): an open‐label, international, randomised controlled trial publication-title: Lancet Oncol – volume: 11 start-page: 601 year: 2002 end-page: 615 article-title: Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I publication-title: J Womens Health Gend Based Med – volume: 22 start-page: 681 year: 2011 end-page: 688 article-title: Relationship between height at diagnosis and bone tumors in young people: a meta‐analysis publication-title: Cancer Causes Control – volume: 4 start-page: 12 year: 2018 article-title: Osteosarcoma: a comprehensive review publication-title: SICOT J – volume: 12 start-page: 11178 year: 2015 end-page: 11195 article-title: High birth weight increases the risk for bone tumor: a systematic review and meta‐analysis publication-title: Int J Environ Res Public Health – volume: 50 start-page: 147 year: 2014 end-page: 153 article-title: Osteosarcomas of the jaws differ from their peripheral counterparts and require a distinct treatment approach. Experiences from the DOESAK Registry publication-title: Oral Oncol – volume: 137 start-page: 423 year: 2019 end-page: 429 article-title: Lung metastases at the initial diagnosis of high‐grade osteosarcoma: prevalence, risk factors and prognostic factors. A large population‐based cohort study publication-title: Sao Paulo Med J – volume: 41 start-page: 390 year: 2012 end-page: 399 article-title: Demographic determinants of survival in osteosarcoma publication-title: Ann Acad Med Singap – volume: 9 year: 2017 article-title: Demographics of head and neck cancer patients: a single institution experience publication-title: Cureus – volume: 107 year: 2015 article-title: Germline TP53 variants and susceptibility to osteosarcoma publication-title: J Natl Cancer Inst – volume: 125 start-page: 229 year: 2009 end-page: 234 article-title: International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons publication-title: Int J Cancer – volume: 109 start-page: 36 year: 2019 end-page: 50 article-title: Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS‐1 (European and American Osteosarcoma Study) cohort publication-title: Eur J Cancer – volume: 115 start-page: 1531 year: 2009 end-page: 1543 article-title: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program publication-title: Cancer – volume: 20 start-page: 1770 year: 2011 end-page: 1777 article-title: Age‐period‐cohort analysis of primary bone cancer incidence rates in the United States (1976‐2005) publication-title: Cancer Epidemiol Biomarkers Prev – volume: 38 start-page: 259 year: 2020 end-page: 269 article-title: Epidemiology and risk factors of osteosarcoma publication-title: Cancer Invest – year: 2020 – volume: 4 start-page: 46 year: 2019 article-title: Primary tumor resection in patients with metastatic osteosarcoma publication-title: Ann Joint – volume: 17 start-page: 1070 year: 2016 end-page: 1080 article-title: Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open‐label, phase 3 trial publication-title: Lancet Oncol – volume: 39 start-page: 593 year: 2015 end-page: 599 article-title: Prognostic factors for survival in patients with high‐grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database publication-title: Cancer Epidemiol – volume: 26 year: 2019 article-title: Characteristics and prognostic factors of patients with osteosarcoma older than 60 years from the SEER database publication-title: Cancer Control – volume: 26 start-page: 5368 year: 2008 end-page: 5373 article-title: Osteosarcoma in patients older than 65 years publication-title: J Clin Oncol – volume: 7 start-page: 4773 year: 2018 end-page: 4780 article-title: A comparison of relative survival and cause‐specific survival methods to measure net survival in cancer populations publication-title: Cancer Med – volume: 20 start-page: 1136 year: 2009 end-page: 1141 article-title: Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases publication-title: Ann Oncol – volume: 22 start-page: 899 year: 2011 end-page: 908 article-title: Height at diagnosis and birth‐weight as risk factors for osteosarcoma publication-title: Cancer Causes Control – volume: 55 start-page: 285 year: 2010 end-page: 289 article-title: Osteosarcoma in children 5 years of age or younger at initial diagnosis publication-title: Pediatr Blood Cancer – volume: 11 start-page: 617 year: 2002 end-page: 629 article-title: Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II publication-title: J Womens Health Gend Based Med – volume: 278 start-page: 1262 year: 1997 end-page: 1267 article-title: Cancer incidence after retinoblastoma: radiation dose and sarcoma risk publication-title: JAMA – volume: 156 year: 2020 article-title: Osteosarcoma of the jaws: an overview of the pathophysiological mechanisms publication-title: Crit Rev Oncol Hematol – volume: 13 start-page: 480 year: 2017 end-page: 491 article-title: Germline and somatic genetics of osteosarcoma ‐ connecting etiology, biology and therapy publication-title: Nat Rev Endocrinol – volume-title: SEER*Stat Software. Version 8.3.8 year: 2020 ident: e_1_2_8_20_1 – ident: e_1_2_8_31_1 doi: 10.1200/jco.2007.14.9104 – ident: e_1_2_8_27_1 doi: 10.1002/jso.22122 – ident: e_1_2_8_6_1 doi: 10.3390/ijerph120911178 – ident: e_1_2_8_16_1 doi: 10.7150/jca.32627 – ident: e_1_2_8_26_1 doi: 10.1016/j.ejca.2018.11.027 – ident: e_1_2_8_34_1 doi: 10.1007/s11864‐009‐0087‐3 – ident: e_1_2_8_2_1 doi: 10.1002/cncr.24121 – ident: e_1_2_8_22_1 doi: 10.1002/cam4.1706 – ident: e_1_2_8_41_1 doi: 10.1016/s1470‐2045(16)30096‐1 – ident: e_1_2_8_32_1 doi: 10.1590/1516‐3180.2018.0381120619 – ident: e_1_2_8_8_1 doi: 10.1001/jama.1997.03550150066037 – ident: e_1_2_8_35_1 doi: 10.47102/annals-acadmedsg.V41N9p390 – ident: e_1_2_8_3_1 doi: 10.1002/(sici)1097‐0215(19980729)77:3<370::aid‐ijc11>3.0.co;2‐c – ident: e_1_2_8_10_1 doi: 10.1093/jnci/djv101 – volume-title: SEER*Stat Database: Incidence–SEER Research Data, 9 Registries, 2019 Sub (1975‐2017)–Linked to County Attributes–Time Dependent (1990‐2017) Income/Rurality, 1969‐2017 Counties year: 2020 ident: e_1_2_8_19_1 – ident: e_1_2_8_13_1 doi: 10.1002/pbc.22509 – ident: e_1_2_8_21_1 doi: 10.1001/jamaoncol.2020.0197 – ident: e_1_2_8_44_1 doi: 10.1038/nrclinonc.2014.175 – ident: e_1_2_8_30_1 doi: 10.1038/nrendo.2017.16 – ident: e_1_2_8_40_1 doi: 10.1200/jco.2014.60.0734 – ident: e_1_2_8_36_1 doi: 10.1089/152460902760360568 – ident: e_1_2_8_43_1 doi: 10.3892/mco.2018.1752 – ident: e_1_2_8_42_1 doi: 10.3390/jcm10061182 – ident: e_1_2_8_5_1 doi: 10.1007/s10552‐011‐9740‐9 – ident: e_1_2_8_25_1 doi: 10.1093/annonc/mdn731 – ident: e_1_2_8_28_1 doi: 10.1001/archsurg.1992.01420120013002 – ident: e_1_2_8_39_1 doi: 10.1016/s1470‐2045(16)30214‐5 – ident: e_1_2_8_4_1 doi: 10.1007/s10552-011-9763-2 – ident: e_1_2_8_29_1 doi: 10.1016/j.critrevonc.2020.103126 – ident: e_1_2_8_38_1 doi: 10.1016/j.oraloncology.2013.10.017 – ident: e_1_2_8_18_1 doi: 10.1080/07357907.2020.1768401 – ident: e_1_2_8_9_1 doi: 10.1001/jamaoncol.2020.0197 – ident: e_1_2_8_23_1 doi: 10.1051/sicotj/2017028 – ident: e_1_2_8_14_1 doi: 10.1002/ijc.24320 – ident: e_1_2_8_37_1 doi: 10.1089/152460902760360559 – ident: e_1_2_8_7_1 doi: 10.1002/cncr.30248 – ident: e_1_2_8_17_1 doi: 10.1016/j.canep.2015.05.001 – ident: e_1_2_8_33_1 doi: 10.21037/aoj.2019.12.03 – ident: e_1_2_8_12_1 doi: 10.1002/cam4.1659 – ident: e_1_2_8_45_1 doi: 10.7759/cureus.1418 – ident: e_1_2_8_11_1 doi: 10.1177/1073274819888893 – ident: e_1_2_8_24_1 doi: 10.2307/2531329 – ident: e_1_2_8_15_1 doi: 10.1158/1055‐9965.epi‐11‐0136 |
| SSID | ssj0007253 |
| Score | 2.6866815 |
| Snippet | Background
Osteosarcoma is the most common primary bone malignancy. As a rare cancer, population‐based studies remain small with limited information on finer... Important differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are... Osteosarcoma is the most common primary bone malignancy. As a rare cancer, population-based studies remain small with limited information on finer demographic... BackgroundOsteosarcoma is the most common primary bone malignancy. As a rare cancer, population‐based studies remain small with limited information on finer... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2107 |
| SubjectTerms | Adolescent Adult Age Aged Biomedical materials Bone cancer Bone Neoplasms - epidemiology Bone Neoplasms - genetics Cancer Child Child, Preschool Children Demographics Demography Epidemiology Ethnic factors Ethnicity Humans Incidence Infant Infant, Newborn Male Malignancy Metastases Middle Aged Minority & ethnic groups Oncology Osteosarcoma Osteosarcoma - epidemiology Osteosarcoma - genetics Population studies Population-based studies Rare diseases Risk analysis Risk factors Risk groups Sarcoma SEER SEER Program Surveillance Survival Tumors United States - epidemiology Young Adult |
| Title | Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017 |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.34163 https://www.ncbi.nlm.nih.gov/pubmed/35226758 https://www.proquest.com/docview/2660943404 https://www.proquest.com/docview/2634849360 https://pubmed.ncbi.nlm.nih.gov/PMC11647566 |
| Volume | 128 |
| WOSCitedRecordID | wos000761951200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1097-0142 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1097-0142 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba9RAFD60WxFfvGujtYzoi9K0yWSSmRFfyrqLgq6yWty3kLkEC20im92Cb_4Ef6O_xDOTbNalIogPgYQ5Q-Zyzpxvbt8BeMocYwFOrUItTRYydGmhUDQLY0MjZqmykYp8sAk-mYjZTH7YgperuzAtP0S_4OYsw4_XzsAL1RytSUN1peeHicMT27BDUXHTAey8mo5P3vYjMacdC2UkwpQls56elB6tc286pEso8_Jhyd9BrPdC4xv_V_6bcL1Dn-S4VZdbsGWr23D1Xbe_fgfK99jpdYPKX58XL8gx-bicX1gXmAh144CM1uFkvx2QojJkhM_UNsuzRUO6o14_v_9wrtFgest3QtwVFhJLnpJFTRAK8LtwMh59Gr4Ou0gMoWZMJiGzaPc6KhWTZVrgsKB4bAVVUlFmIkW5SDWXqU40z3RqjNKSZsYU3KLvU4gR78Ggqiu7CwSnZ7FQojAZNyw2EhEft7RMOWYpM0oDeLbqjlx3NOUuWsZZ3hIs09w1XO4bLoAnvezXlpzjj1J7q17NOwNtcsQl7kwli1gAj_tkNC23X1JUtl46mYQJrH4WBXC_VYL-Nx634lwrALGhHr2Ao-3eTKlOv3j67thRuCGKDuC514-_FD0fToZT__bgX4QfwjXqbmn4xaI9GCzmS_sIruiLxWkz34dtPhP7na3g1-c3k1_GJBcu |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB5BQcCl_JdAASO4gBqaOE5sc6tWW7WiDagUsbco_olaqSRos1uptz4Cz9gnYeykWVZFSIhDpEgeK4494_lsj78BeMMcYwEurUItTRYydGmhUDQLY0MjZqmykYp8sgme52IykZ_72Bx3F6bjhxg23Jxl-PnaGbjbkN5csIbqWk_fJw5QXIcbDJGGy9zwbTcfJmJOexLKSIQpSyYDOyndXNRd9kdXQObVWMnfMax3Qtt3_7P592C1R59kq1OX-3DN1g_g1n5_vv4Qqk846E2Lyt98Lz-QLfJlPj21LjER6sYGGS_SyZ5tkLI2ZIzPgW3nJ7OW9KFeF-c_nWs0WN7xnRB3hYXEkqdk1hCEAvwRfN0eH452wj4TQ6gZk0nILNq9jirFZJWWOC0oHltBlVSUmUhRLlLNZaoTzTOdGqO0pJkxJbfo-xRixMewUje1fQIEl2exUKI0GTcsNhIRH7e0SjlWqTJKA3h7OR6F7mnKXbaMk6IjWKaF67jCd1wArwfZHx05xx-l1i-HtegNtC0Ql7iYShaxAF4NxWha7rykrG0zdzIJE_j7WRTAWqcFw2c8bsW1VgBiST8GAUfbvVxSHx95-u7YUbghig7gnVeQvzS9GOWjA__29F-EX8LtncP9vWJvN__4DO5Qd2PDbxytw8psOrfP4aY-nR230xfeYH4B3xsX-Q |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB7BFlVc-C8NFDCCC6ihiePEDrdquysQZakWKu0tin8iKrVJtdmtxI1H4Bl5EsaOm2VVhIQ4RIrksRLbM57P9vgbgJfMMhbg0ipUuc5Chi4tFJJmYaxpxAyVJpKRSzbBJxMxm-VHPjbH3oXp-CH6DTdrGW6-tgZuznW1t2INVbWav0ksoLgOG8xmkRnAxsF0fHzYT8WcehrKSIQpS2Y9PyndW9Ve90hXYObVaMnfUaxzQ-Pb_9mAO3DL40-y3ynMXbhm6nuw-dGfsN-H6hMOe9Oi-jdn5VuyTz4v5xfGpiZC7dglo1VC2W-7pKw1GeEzNe3ydNESH-z18_sP6xw1lneMJ8ReYiFxzlOyaAiCAf4AjsejL8N3oc_FECrG8iRkBi1fRZVkeZWWODFIHhtBZS4p05GkXKSK56lKFM9UqrVUOc20LrlB7ycRJW7BoG5qsw0EF2ixkKLUGdcs1jliPm5olXKsUmWUBvDqcjwK5YnKbb6M06KjWKaF7bjCdVwAL3rZ846e449SO5fDWngTbQtEJjaqkkUsgOd9MRqXPTEpa9MsrUzCBDY_iwJ42GlB_xmHXHG1FYBY049ewBJ3r5fUJ18dgXdsSdwQRwfw2inIX369GE6GU_f26F-En8Hm0cG4OHw_-fAYblJ7ZcPtHO3AYDFfmidwQ10sTtr5U28xvwCzSxii |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Osteosarcoma%3A+A+Surveillance%2C+Epidemiology%2C+and+End+Results+program-based+analysis+from+1975+to+2017&rft.jtitle=Cancer&rft.au=Cole%2C+Sarah&rft.au=Gianferante%2C+D.+Matthew&rft.au=Zhu%2C+Bin&rft.au=Mirabello%2C+Lisa&rft.date=2022-06-01&rft.issn=0008-543X&rft.eissn=1097-0142&rft.volume=128&rft.issue=11&rft.spage=2107&rft.epage=2118&rft_id=info:doi/10.1002%2Fcncr.34163&rft_id=info%3Apmid%2F35226758&rft.externalDocID=PMC11647566 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |